An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)

Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin® as 1st Line Therapy (Post-HERMINE Study)

This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.

Inclusion Criteria:

• Female patient, >/= 18 years of age
• Metastatic breast cancer
• 1st-line treatment with Herceptin initiated in 2002
• Included in pharmaco-epidemiologic HERMINE study

Exclusion Criteria:

• Patient died before scheduled follow-up visit (March 2005)